Episode 47
This week, hosts Daphne Zohar, Josh Schimmer, Dawn Bell and Sam Fazeli cover recent biotech earnings, big pharma revenue drivers, FDA news, data and much more. The group kicks off the conversation by addressing the slow week in M&A news before diving into the profitability of Medicare Advantage for…
Episode 46
On this week’s episode, hosts Daphne Zohar and Josh Schimmer welcome founder and former CEO of Alnylam, John Maraganore, as a guest, and are joined by Ethan Perlstein, Rob Perez, Michal Preminger and Chris Garabedian. The discussion begins with a recap from John’s recent op-ed article published in …
Ep. 20: Ethan Perlstein on the Role of Families in Research Funding and 1-to-N Medicine
In this episode, VibeCast host Ray Dogum speaks with Ethan Perlstein, PhD about the Role of Families in Research Funding, 1-to-N Medicine, Clinical Trials, and the Challenges of Funding Rare Disease Research.
Guest Bio:
Ethan O. Perlstein received a PhD in 2006 from Harvard University (Department …
Episode 69
On Biotech Hangout this week, Brad Loncar, Chris Garabedian, Sam Fazeli, Rob Perez and Ethan Perlstein discuss the influence of GLP-1s including cost, safety, drawbacks and more in light of Novo Nordisk’s positive semaglutide SELECT study results and Eli Lilly’s earnings, which rose due to their ty…
Episode 81
On this week’s episode of Biotech Hangout hosts Daphne Zohar, Tim Opler, Josh Schimmer, Chris Garabedian, John Maraganore and Ethan Perlstein discuss the latest industry news including takeaways and sentiment from the recent Jefferies, Stifel, American Heart Association and ACR conferences. They al…
Episode 90
On this week’s Biotech Hangout, hosts Daphne Zohar, Tim Opler, Dawn Bell, Ethan Perlstein and Eric Schmidt discuss the latest in biotech news, including the overall performance of IPOs this year, including Metagenomi’s IPO this week and what it means for the IPO window. The hosts also debate the va…
Decentralized Science vs. Rare Diseases: A Game-Changer? | Ethan Perlstein
Welcome to another episode of the DeSci Podcast. Today, we are discussing a critical issue that affects over 30 million people in the United States—Rare Diseases. Despite being more prevalent than cancer and HIV combined, rare diseases remain underfunded, overlooked by Big Pharma, and trapped in a …
Biotech on the Blockchain: Rare Disease Solutions with Dr. Ethan Perlstein
In this episode, we interview Dr. Ethan Perlstein, founder and CEO of Curetopia, about his mission to end rare genetic diseases. Dr. Perlstein shares his journey as a scientist, builder, and investor, and discusses Curetopia's innovative approach to drug development, including the use of blockchain…
YC Biotech Founder Wants to End All Rare Disease - Ethan Perlstein (Ep. 11)
In this episode, I talk to Ethan Perlstein, a YC biotech founder who wants to make better drugs and financial incentives for curing rare diseases. We discuss the post-academic collapse in science careers, the financial abandonment of most rare diseases, and how crypto and AI could revolutionize dru…
Exploring cell membranes through dish detergent - Ethan Perlstein
View full lesson: http://ed.ted.com/lessons/insights-into-cell-membranes-via-dish-detergent-ethan-perlsteinThe cell membrane, like a good jacket, protects the cell from everything outside of it. How is it simultaneously sturdy, flexible, and capable of allowing the right things to pass through? Et…
PODCAST SEARCH ENGINE
You can use our website to search 3,826,623 podcasts and 196,124,220 episodes by people, places, or topics.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
EDIT
Thank you for helping to keep the podcast database up to date.
